Navigation Links
Tolerx Named as One of the 'Fierce 15' Biotech Companies of 2008
Date:6/24/2008

ceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. Tolerx currently has two antibodies in clinical development for the potential treatment of various autoimmune indications: otelixizumab, an anti-CD3 MAb which is being developed in collaboration with GlaxoSmithKline and a modified form of TRX1, which is being developed in collaboration with Genentech, Inc. Tolerx is also engaged in preclinical development of new product candidates that circumvent immune system tolerance. These product candidates are being evaluated for the treatment of cancer or chronic viral diseases. For more information, please visit http://www.tolerx.com.

Tolerx Forward-Looking Statements

This press release contains certain statements that include the word "potential". Such statements, which are not historical facts, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Statements regarding outcomes sought to be realized in the clinical trials or preclinical development, and the potential for Tolerx to make a significant impact in the biotech market are all forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Tolerx to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. There can be no certainty that Tolerx will advance any clinical candidate or other component of its pipeline to the clinic, to the next regulatory step or to commercialization or that Tolerx will ever realize revenue from commercialization of product candidates it is currently or may in the future seek to develop. Factors and risks that may impact management's expectations and affect the forward-looking statements include but are not be limit
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
2. Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
3. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
4. Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association
5. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
6. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
7. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
8. Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners
9. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
10. Ash Stevens Inc. Named One of Michigan 50 Companies to Watch
11. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SAN CARLOS, Calif. , Aug. 4, 2015 /PRNewswire/ ... non-invasive genetic testing and the analysis of circulating cell-free ... its second quarter ended June 30, 2015 after the ... a conference call and webcast at 1:30 p.m. PT ... activities and financial outlook.Event:Natera,s Second Quarter 2015 Results Conference ...
(Date:8/3/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast ... 2015 on Monday, August 10, 2015 at 4:30 p.m. ... and chief executive officer, will lead the call. On ... for the second quarter 2015. The call ... Halozyme,s corporate website and a recording will be made ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... consumer of benzene. Benzene is processed to get such derivatives as ethylbenzene, a ... derivatives are principally used within the automotive industry for the production of tyres ...
(Date:8/3/2015)... , August 3, 2015 E-QURE ... commercialization of its Bio-electrical Signal Therapy device ("BST Device"), ... of hard to heal chronic wounds, today announced that ... Chemipal, an Israeli distributor specializing in medical devices, for ... Chemipal is a 70 years old, sales, marketing ...
Breaking Biology Technology:Natera to Release Second Quarter 2015 Results on August 12, 2015 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3
... TE 70, TE 77, TE 70 PWR, TE 77 PWR , ... transfer results using low current and voltage with a minimal amount of buffer. ... with and without built-in power supplies to give maximum flexibility , ... from polyacrylamide gels in less than 1 h , ...
... , ... DIGE Imager • fluorescent Western blotting • multiplex detection • dynamic ... The Ettan™ DIGE Imager is fully compatible with ... and dynamic range as the Typhoon™ scanner. Similar results are also ...
... , Key words: ... Beads, , ... pituitary and are processed into three major peptide hormone fragments: adrenocorticotrophin ... hormones are known to activate the MC 5 (melanocortin subtype ...
Cached Biology Technology:ECL Semi-dry Blotters 2Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 2Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 3Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 4Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 5Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 6Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 7Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 8The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 2The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 3The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 4The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 5
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... 29, 2013) Pregnant women with mid to high ... are at risk for having babies with reduced fetal ... in Gastroenterology , the official journal of the ... most commonly found in patients with celiac disease. ...
... April 29, 2013 Research and ... "Gesture Recognition & Touchless Sensing Market (2013 - ... Product (Biometric, Sanitary Equipment); Application (Healthcare, Consumer Electronics, ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ...
... an effective herbal remedy useful for weight control and helping ... ascertain whether green tea truly has this potential, Jae-Hyung Park ... in the Republic of Korea conducted a study, now published ... The active constituents of green tea, which have been ...
Cached Biology News:Pregnant women with high celiac disease antibodies are at risk for low birth weight babies 2Gesture Recognition & Touchless Sensing Market (2013 - 2018): By Technology, Product, Application and Geography 2Gesture Recognition & Touchless Sensing Market (2013 - 2018): By Technology, Product, Application and Geography 3Will green tea help you lose weight? 2
ID clarifier: Without ethidium bromide...
... Biotin Streptavidin-HRP Systems provide rapid, precise ... antigens in frozen or paraffin-embedded tissue, ... systems also facilitate double or triple ... performed simultaneously with primary antibodies of ...
...
... covers can be used with ... covers for stacking of covered ... for use with automated systems ... and non-ridged, are available for ...
Biology Products: